Serum IL-17 and postmenopausal osteoporosis
DOI:
https://doi.org/10.32007/jfacmedbagdad.574394Keywords:
Postmenopasual, Osteoporosis, IL-17.Abstract
Background: Osteoporosis is a bone condition that makes bones thininer and more fragile because of reduced bone density and it puts people at risk of fractures, especially of the hip, spinal vertebrae and wrist.
Objective: This study will highlighted the role of IL-17 in postmenopausal osteoporosis.
Patients and methods: This study applied on 84 includes subjects (42 postmenopausal osteoporosis patient and 42 of healthy control group), conducted from December 2014 to March 2015 to measure the IL-17 serum level by using ELISA kit.
Results: In osteoporotic postmenopausal women the mean of serum IL-17 was (0.49pg/ml) and it is significantly higher than that of healthy group (0.09pg/ml).
Conclusion: Serum IL-17 was significantly elevated in osteoporotic postmenopausal women when compared to healthy postmenopausal women.
Downloads
Downloads
Published
Issue
Section
License
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.